Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Non-Current Assets: 2009-2025

Historic Non-Current Assets for Aytu Biopharma (AYTU) over the last 17 years, with Jun 2025 value amounting to $45.0 million.

  • Aytu Biopharma's Non-Current Assets fell 20.35% to $43.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.9 million, marking a year-over-year decrease of 20.35%. This contributed to the annual value of $45.0 million for FY2025, which is 19.94% down from last year.
  • Latest data reveals that Aytu Biopharma reported Non-Current Assets of $45.0 million as of FY2025, which was down 19.94% from $56.2 million recorded in FY2024.
  • Over the past 5 years, Aytu Biopharma's Non-Current Assets peaked at $160.4 million during FY2021, and registered a low of $45.0 million during FY2025.
  • Its 3-year average for Non-Current Assets is $55.5 million, with a median of $56.2 million in 2024.
  • In the last 5 years, Aytu Biopharma's Non-Current Assets soared by 106.03% in 2021 and then crashed by 51.57% in 2022.
  • Yearly analysis of 5 years shows Aytu Biopharma's Non-Current Assets stood at $160.4 million in 2021, then tumbled by 51.57% to $77.7 million in 2022, then fell by 15.84% to $65.4 million in 2023, then decreased by 14.04% to $56.2 million in 2024, then dropped by 19.94% to $45.0 million in 2025.